CA
NZ
UK
AU
IND
US
The fall followed a Form 8-K lodged the previous day disclosing that an unauthorised third party had accessed files on the company's corporate file server.
CareCloud trades barely changed on the day and nearer the floor of a 52-week range topping out at US$4.01, an awkward place for a micro-cap that has just retired its most expensive layer of capital without issuing a share.
Twist Bioscience Corp (NASDAQ: TWST) reported exceptional results for its fiscal third quarter, achieving revenue of $118.4 million. This represents a more than 23% increase compared to $96.1 million in the same quarter last year. The performance comes amidst heightened investor interest, given that …
Early tolerability confirms the dosing strategy and gives investors a clearer view of the therapy’s risk profile. The absence of serious events removes a key barrier and positions the program for accelerated regulatory dialogue.
This substantial figure reflects the company's ongoingInvestmentin clinical trials while highlighting the challenges it faces as a clinical-stage therapeutic developer. Despite the loss, investors may find promise in the progress of its lead projects, which are on track for key milestones in the coming …
This adjustment enables the warrants' holders to have a more favorable entry point into the company’s stock, reflecting Sunshine Biopharma’s proactive market strategy. For investors, this change fosters renewed interest in the stock and potential liquidity.
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) has entered into a merger agreement with Indivior Pharmaceuticals, creating a combined entity that will see Supernus stockholders exchange each share for 1.5401 shares of Indivior stock. This strategic merger marks a significant shift, allowing Supernus to continue operating …
TG Therapeutics, Inc. (Nasdaq: TGTX) has delivered an impressive second-quarter performance, reporting a total global revenue of approximately $240 million. The company has raised its full-year 2026 revenue guidance to approximately $950 million, bolstered by strong demand for its flagship product. This optimistic outlook …
This growth aligns with a strong shift toward a recurring revenue model, driven primarily by the Integrated Service Program (ISP). The ISP revenue surged 86.4% to $491,399, positioning it as a key growth driver. Such an uptick reveals an expanding market acceptance of QHSLab’s …
Autolus Therapeutics plc (NASDAQ: AUTL) closed a senior secured notes facility worth up to $250 million and immediately issued a $75 million first tranche, dramatically widening its cash resources. The agreement also authorizes three additional tranches totalling $175 million, contingent on future revenue milestones.
Please wait processing your request...